CTCE 9908

CTCE 9908 acts as a CXCR4 antagonist that induces mitotic catastrophe in ovarian cancer cells. When given with taxol, it displays additive cytotoxic effects.

Designed for biological research and industrial applications, not intended for individual clinical or medical purposes.
CTCE 9908(CAS 1030384-98-5)

CAT No: R0977

CAS No:1030384-98-5

Synonyms/Alias:CTCE 9908;1030384-98-5;CTCE-9908;UNII-NF0BX95A31;L-Lysinamide, N2,N6-bis(L-lysylglycyl-L-valyl-L-seryl-L-leucyl-L-seryl-L-tyrosyl-L-arginyl)-;NF0BX95A31;PTX-9908 FREE BASE;CTCE 9908 TFA;CTCE9908;SDF-1 Analog PTX-9908;CHEMBL3544949;SDF-1 (108) Lysine Dlmer;CXCR4 Antagonist CTCE-9908;PTX9908;PTX 9908;PTX-9908;SDF-1 Receptor Antagonist PTX-9908;DA-52152;G14352;Q27284835;L-Lysinamide,N2,N6-bis(L-lysylglycyl-L-valyl-L-seryl-L-leucyl-L-seryl-L-tyrosyl-L-arginyl)-;

Custom Peptide Synthesis
cGMP Peptide
  • Registration of APIs
  • CMC information required for an IND
  • IND and NDA support
  • Drug master files (DMF) filing
M.F/Formula
C86H147N27O23
M.W/Mr.
1927.3
Sequence
Three Letter Code:H-Lys-Gly-Val-Ser-Leu-Ser-Tyr-Arg-Lys(1)-NH2.H-Lys-Gly-Val-Ser-Leu-Ser-Tyr-Arg-(1)
Labeling Target
CXCR4
Appearance
White lyophilised solid
Purity
>98%
Activity
Antagonist
Long-term Storage Conditions
Soluble in water
InChI
InChI=1S/C86H147N27O23/c1-45(2)35-58(104-81(133)64(43-116)110-83(135)68(47(5)6)112-66(120)39-99-71(123)53(89)17-9-12-30-87)75(127)108-62(41-114)79(131)106-60(37-49-22-26-51(118)27-23-49)77(129)102-56(20-15-33-97-85(92)93)73(125)96-32-14-11-19-55(70(91)122)101-74(126)57(21-16-34-98-86(94)95)103-78(130)61(38-50-24-28-52(119)29-25-50)107-80(132)63(42-115)109-76(128)59(36-46(3)4)105-82(134)65(44-117)111-84(136)69(48(7)8)113-67(121)40-100-72(124)54(90)18-10-13-31-88/h22-29,45-48,53-65,68-69,114-119H,9-21,30-44,87-90H2,1-8H3,(H2,91,122)(H,96,125)(H,99,123)(H,100,124)(H,101,126)(H,102,129)(H,103,130)(H,104,133)(H,105,134)(H,106,131)(H,107,132)(H,108,127)(H,109,128)(H,110,135)(H,111,136)(H,112,120)(H,113,121)(H4,92,93,97)(H4,94,95,98)/t53-,54-,55-,56-,57-,58-,59-,60-,61-,62-,63-,64-,65-,68-,69-/m0/s1
InChI Key
VUYRSKROGTWHDC-HZGLMRDYSA-N
Isomeric SMILES
CC(C)C[C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)N[C@@H](CCCNC(=N)N)C(=O)NCCCC[C@@H](C(=O)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CC2=CC=C(C=C2)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCCCN)N)NC(=O)[C@H](CO)NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCCCN)N

Useful Tools

Peptide Calculator

Abbreviation List

Peptide Glossary

If you have any peptide synthesis requirement in mind, please do not hesitate to contact us at . We will endeavor to provide highly satisfying products and services.

Featured Services
Peptide Analysis ServicesPeptide Modification ServicesPeptide Nucleic Acids SynthesisPeptide CDMOCustom Conjugation ServicecGMP Peptide ServiceEpitope Mapping ServicesPeptide Synthesis Services
Hot Products
About us

Creative Peptides is a trusted CDMO partner specializing in high-quality peptide synthesis, conjugation, and manufacturing under strict cGMP compliance. With advanced technology platforms and a team of experienced scientists, we deliver tailored peptide solutions to support drug discovery, clinical development, and cosmetic innovation worldwide.

From custom peptide synthesis to complex peptide-drug conjugates, we provide flexible, end-to-end services designed to accelerate timelines and ensure regulatory excellence. Our commitment to quality, reliability, and innovation has made us a preferred partner across the pharmaceutical, biotechnology, and personal care industries.

Our Customers